drugset
drugset / Trial / NCT01709734

A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

NCT01709734 ↗

Phase 2 Terminated 126 enrolled LTN PHARMACEUTICALS, INC.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

A Phase 2, 2 part trial to evaluate the safety and efficacy of galeterone in castration resistant prostate cancer (CRPC) patients.

Timeline

Start
2012-12
Primary completion
2016-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject galeterone Small molecule — Oral

Indications

prostate cancer